image
AptarGroup, Inc. ATR
Healthcare - Medical - Instruments & Supplies - NYSE - US
Watchlist
$ 161.04
0.449 %
$ 10.6 B
Market Cap
29.44
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ATR stock under the worst case scenario is HIDDEN Compared to the current market price of 161 USD, AptarGroup, Inc. is HIDDEN

ATR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ATR stock under the base case scenario is HIDDEN Compared to the current market price of 161 USD, AptarGroup, Inc. is HIDDEN

ATR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ATR stock under the best case scenario is HIDDEN Compared to the current market price of 161 USD, AptarGroup, Inc. is HIDDEN

ATR Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ATR

image
1M 5%
6M 4%
1Y 16%
3Y 67%
5Y 49%
All
$165.0$165.0$160.0$160.0$155.0$155.0$150.0$150.0$145.0$145.0$140.0$140.0$135.0$135.0$130.0$130.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
3.58 B REVENUE
2.74%
Growth Rates
1Year 2.74%
3Years 3.55%
5Years 4.61%
7Years 5.46%
10Years 3.27%
496 M OPERATING INCOME
22.89%
Growth Rates
1Year 22.89%
3Years 12.65%
5Years 5.96%
7Years 6.40%
10Years 4.94%
374 M NET INCOME
31.67%
Growth Rates
1Year 31.67%
3Years 15.37%
5Years 9.09%
7Years 7.88%
10Years 6.92%
643 M OPERATING CASH FLOW
11.85%
Growth Rates
1Year 11.85%
3Years 20.97%
5Years 4.58%
7Years 10.26%
10Years 7.42%
-397 M INVESTING CASH FLOW
-22.27%
Growth Rates
1Year -22.27%
3Years 4.62%
5Years -3.36%
7Years -8.45%
10Years -9.56%
-225 M FINANCING CASH FLOW
-31.35%
Growth Rates
1Year -31.35%
3Years -40.35%
5Years -2.71%
7Years -16.79%
10Years -28.09%
887 M REVENUE
4.62%
Growth Rates
1Year 2.74%
3Years 3.55%
5Years 4.61%
7Years 5.46%
10Years 3.27%
113 M OPERATING INCOME
-5.54%
Growth Rates
1Year 22.89%
3Years 12.65%
5Years 5.96%
7Years 6.40%
10Years 4.94%
78.7 M NET INCOME
-21.88%
Growth Rates
1Year 31.67%
3Years 15.37%
5Years 9.09%
7Years 7.88%
10Years 6.92%
82.7 M OPERATING CASH FLOW
-53.58%
Growth Rates
1Year 11.85%
3Years 20.97%
5Years 4.58%
7Years 10.26%
10Years 7.42%
-56.6 M INVESTING CASH FLOW
66.89%
Growth Rates
1Year -22.27%
3Years 4.62%
5Years -3.36%
7Years -8.45%
10Years -9.56%
-135 M FINANCING CASH FLOW
-53.69%
Growth Rates
1Year -31.35%
3Years -40.35%
5Years -2.71%
7Years -16.79%
10Years -28.09%
Balance Sheet AptarGroup, Inc.
image
Current Assets 1.48 B
Cash & Short-Term Investments 226 M
Receivables 671 M
Other Current Assets 582 M
Non-Current Assets 2.95 B
Long-Term Investments 146 M
PP&E 1.51 B
Other Non-Current Assets 1.3 B
5.10 %15.13 %13.12 %3.30 %34.10 %29.25 %Total Assets$4.4b
Current Liabilities 1.07 B
Accounts Payable 296 M
Short-Term Debt 338 M
Other Current Liabilities 434 M
Non-Current Liabilities 878 M
Long-Term Debt 718 M
Other Non-Current Liabilities 160 M
15.21 %17.38 %22.30 %36.87 %8.25 %Total Liabilities$1.9b
EFFICIENCY
Earnings Waterfall AptarGroup, Inc.
image
Revenue 3.58 B
Cost Of Revenue 2.23 B
Gross Profit 1.36 B
Operating Expenses 859 M
Operating Income 496 M
Other Expenses 122 M
Net Income 374 M
4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(2b)1b(859m)496m(122m)374mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
37.83% GROSS MARGIN
37.83%
Averages
1Year 37.83%
3Years 36.36%
5Years 36.40%
7Years 36.12%
10Years 35.88%
13.86% OPERATING MARGIN
13.86%
Averages
1Year 13.86%
3Years 12.29%
5Years 11.84%
7Years 11.79%
10Years 12.29%
10.45% NET MARGIN
10.45%
Averages
1Year 10.45%
3Years 8.60%
5Years 8.14%
7Years 8.03%
10Years 8.25%
15.15% ROE
15.15%
Averages
1Year 15.15%
3Years 13.04%
5Years 12.62%
7Years 13.17%
10Years 14.38%
8.45% ROA
8.45%
Averages
1Year 8.45%
3Years 6.84%
5Years 6.36%
7Years 6.34%
10Years 6.75%
10.68% ROIC
10.68%
Averages
1Year 10.68%
3Years 8.96%
5Years 8.35%
7Years 8.27%
10Years 8.75%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AptarGroup, Inc.
image
400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 374 M
Depreciation & Amortization 220 M
Capital Expenditures -276 M
Stock-Based Compensation 47.6 M
Change in Working Capital -32.3 M
Others 43.2 M
Free Cash Flow 367 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AptarGroup, Inc.
image
Wall Street analysts predict an average 1-year price target for ATR of $154 , with forecasts ranging from a low of $45 to a high of $215 .
ATR Lowest Price Target Wall Street Target
45 USD -72.06%
ATR Average Price Target Wall Street Target
154 USD -4.64%
ATR Highest Price Target Wall Street Target
215 USD 33.51%
Price
Max Price Target
Min Price Target
Average Price Target
220220200200180180160160140140120120100100808060604040Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
0.30% DIVIDEND YIELD
0.45 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.801.801.601.601.401.401.201.201.001.000.800.800.600.600.400.400.200.200.000.000.280.30.320.320.340.360.360.380.380.410.450.280.30.320.320.360.360.380.380.380.410.450.280.30.320.340.360.360.380.380.410.450.31.140.321.220.321.280.341.320.361.420.361.440.381.500.381.520.411.580.451.720.902015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership AptarGroup, Inc.
image
Sold
0-3 MONTHS
8.38 M USD 7
3-6 MONTHS
0 USD 0
6-9 MONTHS
6.29 M USD 4
9-12 MONTHS
15.3 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR PRINCETON, N.J. , July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada. prnewswire.com - 1 week ago
Aptar Named One of the World's Most Sustainable Companies by TIME for Second Consecutive Year CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of the World's Most Sustainable Companies by TIME for Second Consecutive Year. businesswire.com - 1 week ago
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR PRINCETON, N.J. , June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device,  (the denial letter). prnewswire.com - 2 weeks ago
Top 3 Earnings Growth Stocks for Investment AEM, ATR, and VICI stand out with rising earnings forecasts and solid growth, pointing to bullish investor potential. zacks.com - 2 weeks ago
AptarGroup (ATR) Upgraded to Strong Buy: Here's Why AptarGroup (ATR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 weeks ago
ATR and RTX's Pratt & Whitney Canada collaborate on propulsion technology to advance next-generation regional turboprops Companies will target continued improvements to aircraft fuel efficiency, durability and operating costs PARIS , June 16, 2025 /PRNewswire/ -- ATR and Pratt & Whitney Canada today announce their intent to collaborate on the development of advanced propulsion technology for regional turboprop aircraft, shaping the future of low-emission regional aviation. This collaboration aims to leverage and extend the industry-leading performance of ATR aircraft equipped with Pratt & Whitney Canada PW127XT engines and explore technologies for the next-generation aircraft, including ATR's 'EVO' concept. prnewswire.com - 3 weeks ago
Aptar to Participate in Upcoming Investor Conferences CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences. businesswire.com - 1 month ago
Aptar Releases 2024 Corporate Sustainability Report CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today released its 2024 Corporate Sustainability Report entitled Progress Takes Shape. Aptar's report highlights key milestones of its global sustainability strategy across the company's global operations focused on three key pillars: Care - operating with care for employees, communities and the environment by aiming to continuously impr. businesswire.com - 1 month ago
Buy 4 Low-Beta Stocks NGS, LRN, ATR & PM Despite Court Tariff Ruling NGS, LRN, ATR and PM stand out as low-beta picks to weather market uncertainty after a U.S. court rules Trump's global tariffs illegal. zacks.com - 1 month ago
4 Top-Ranked Efficient Stocks to Buy for Solid Gains Amid Volatility Invest in stocks of MVST, SBS, CARG and ATR to tap their high-efficiency levels. zacks.com - 1 month ago
Here's Why You Should Add AptarGroup Stock to Your Portfolio Now ATR gains from its business transformation plan and healthy segmental performance. zacks.com - 1 month ago
Is AptarGroup (ATR) Outperforming Other Industrial Products Stocks This Year? Here is how AptarGroup (ATR) and Epiroc Aktiebolag Unsponsored ADR (EPOKY) have performed compared to their sector so far this year. zacks.com - 1 month ago
8. Profile Summary

AptarGroup, Inc. ATR

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 10.6 B
Dividend Yield 0.30%
Description AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
Contact 265 Exchange Drive, Crystal Lake, IL, 60014 https://www.aptar.com
IPO Date April 23, 1993
Employees 13000
Officers Ms. Xiangwei Gong Executive Vice President of President & Strategic Group Dev. and President of Aptar Asia Mr. Hedi Tlili President of Aptar Closures Ms. Mary Skafidas Senior Vice President of Investor Relations & Communications Mr. Stephan B. Tanda President, Chief Executive Officer & Executive Director Mr. Marc Prieur President of Aptar Beauty Mr. Daniel Richard Ackerman Senior Vice President & Chief Accounting Officer Mr. Gael Touya President of Aptar Pharma Ms. Kimberly Y. Chainey Executive Vice President, Chief Legal Officer & Corporate Secretary Ms. Shiela Pallerne Vinczeller Chief Human Resources Officer Ms. Vanessa Kanu Executive Vice President & Chief Financial Officer